Related Experiment Video
Updated: Sep 11, 2025
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.2K
Novel Medication Ganaxolone for Seizure Disorders
Selia Chowdhury1, Samia Chowdhury2
1Dhaka Medical College, Dhaka, Bangladesh.
Discoveries (Craiova, Romania)
|August 11, 2025
Summary
Ganaxolone, a neuroactive steroid, shows potential in reducing seizure frequency for epilepsy patients. While generally effective, treatment-related adverse events like dizziness and somnolence require further safety and efficacy studies.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Ganaxolone is a neuroactive steroid known to enhance GABAergic inhibition.
- Epilepsy is a neurological disorder characterized by recurrent seizures.
Purpose of the Study:
- To systematically review the efficacy and safety of ganaxolone for seizure resolution.
- To evaluate the general benefit of ganaxolone across various epileptic disorders.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) published up to March 2023.
- Searched databases: PubMed, Google Scholar, European PubMed Central, Cochrane Library, and U.S. National Library of Medicine Clinical Trials.
- Included 12 RCTs involving 1337 patients.
Main Results:
- 26.3% of participants across all trials reported a >50% reduction in seizure frequency.
- The nervous system was most affected by treatment-related adverse events (TRAEs).
- Common TRAEs included dizziness, somnolence, headache, and seizures.
Conclusions:
- Ganaxolone demonstrates potential efficacy in reducing seizure frequency in patients with specific epilepsy types, including CDKL5 deficiency disorder, Lennox-Gastaut syndrome, and Protocadherin 19.
- Further research is necessary to confirm ganaxolone's safety and efficacy in broader patient populations.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
276
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
276
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
646
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
646
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
448
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
448
01:14Antiepileptic Drugs: Glutamate Antagonists
516
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
516
01:26Anxiolytic Drugs: Overview
485
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
485
01:24Epilepsy and Seizures: Overview
280
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
280